And Sam, how have you noticed how broad spread-- Like, is this gonna be like Tylenol is now going to, you know, sometimes they say take six hundred versus four hundred, but we're gonna have like generics also hit that? Or is it only for specialized cancer and other kinds of treatments like that?

Yeah, Sriram, I, I think it's a great question.

Uh, [clears throat] I'd answer it in the following way.

Uh, it, it definitely has started where it's been, you know, the early adoption has been around more specialized drugs, drugs that have an opportunity to really make a profound impact and also serve populations.

And quite frankly, it is also tied to, you know, pharma and their ability to, because of that, come to market quicker, get FDA approval or regulatory approval for, for a drug, right? That's been the motivating factor.

And just to be clear, if I were a pharma executive or from a pharma perspective, precision medicine for a long time was not seen as a friend because for a pharma company, it's like, hey, a drug that works for everyone is the ideal thing.

But the recognition that, you know, often that y- you know, the sort of clinical studies or the evidence that are required are much more difficult across just the generalized population than increasingly we have targeted therapies, particularly for cancer, for other, um, other sorts of diseases too, has led to, you know, the, uh, the rise of the importance of biomarkers, which is tied to then precision medicine being used for, uh, particularly drugs that are, that are, you know, in, in the cancer arena again.

[chuckles]

so.

That's right.

We have a leading franchise for prenatal testing.

There, two of the exciting products that we have is our prequel test for NIPS, what was called NIPT testing.

We launched just last year in Q4 an updated test which allows testing at 8-week gestational age as opposed to conventional 10 or 12 weeks.

That's important because eight weeks happens to be when the mother is already going into, you know, the OBGYN for her standard battery of other blood draws that she's going to have.

We also have a leading carrier screening test, expanded carrier screening test called Foresight, Foresight Universal Plus, which we expanded last year, which allows mothers you know, a provider to look at 39 conditions, including SMA, across more than 272 genes.

What is the potential?